Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Randomized study of once-weekly interferon β-la therapy in relapsing multiple sclerosis: Three-year data from the OWIMS study
Multiple Sclerosis, Volume 11, No. 1, Year 2005
Notification
URL copied to clipboard!
Description
Background: Once weekly interferon β-1a for multiple sclerosis (OWIMS) demonstrated modest, but significant, magnetic resonance imaging (MRI) benefit of once-weekly (qw) interferon (IFN) β-1a at 48 weeks, but no significant effect on relapses. Objective: An OWIMS extension permitted assessment of longer-term efficacy/safety of qw IFN β-1a in relapsing-remitting multiple sclerosis (RRMS). Methods: Placebo patients were rerandomized to IFN β-1a, 22 or 44 mcg qw, for two additional 48-week intervals. Primary outcome was MRI lesion activity. Relapse rate and other MRI measures were secondary outcomes. Results: After three years, median (mean) T2 lesion count/patient/scan was 1.3 (2.6) for 44 mcg, 1.7 (3.3) for 22 mcg, 1.7 (3.4) for placebo/22 mcg, 2.0 (3.6) for placebo/44 mcg (all differences not significant). Annualized relapse rates were lowest for 44 mcg (0.77) versus other groups (0.83-0.86, not significant). Persistent neutralizing antibodies did not affect relapse rates, but MRI active lesions were increased in antibody-positive patients receiving 44 mcg compared to antibody negative patients. Conclusions: In RRMS, once weekly IFN β-1a, particularly 44 mcg, can induce a significant MRI, but not relapse, effect, compared with placebo. No significant dose effect was seen. In contrast to the significant effect observed with three-times-weekly dosing of subcutaneous IFN β-1a compared with placebo, this study confirms the lack of meaningful clinical benefit with once-weekly dosing. © 2005 Edward Arnold (Publishers) Ltd.
Authors & Co-Authors
Freedman, Mark Steven
Canada, Ottawa
L'hôpital D'ottawa
O'Connor, Paul W.
Canada, Toronto
Saint Michael's Hospital University of Toronto
Comi, Giancarlo C.
Italy, Milan
Irccs Ospedale San Raffaele
Duquette, Pierre Pascal
Canada, Montreal
Hôpital Notre-dame
Metz, Luanne M.
Canada, Calgary
Foothills Medical Centre
Bouchard, Jean Pierre
Canada, Quebec
Chu de Québec-université Laval
Abramsky, Oded
Israel, Jerusalem
Hadassah University Medical Centre
Pelletier, Jean B.
France
Centre Hospitalier, France
de Rijk-van Andel, Johanneke F.
Unknown Affiliation
Houston, Patricia L.
Canada, Toronto
Saint Michael's Hospital University of Toronto
Poggi, Alessandro
Italy, Milan
Irccs Ospedale San Raffaele
Demchuk, Andrew M.
Canada, Calgary
Foothills Medical Centre
Karussis, Dimitrios M.
Israel, Jerusalem
Hadassah University Medical Centre
Nelson, Robert F.
Canada, Ottawa
L'hôpital D'ottawa
Ammoury, N.
Switzerland, Geneva
Serono International sa
Hyde, Robert
Switzerland, Geneva
Serono International sa
Statistics
Citations: 41
Authors: 16
Affiliations: 14
Identifiers
Doi:
10.1191/1352458505ms1126oa
ISSN:
13524585
Research Areas
Health System And Policy